NCT01681940

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Zymenex A/S · Industry
• Sex: All
• Age: 5 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis

Conditions

• Alpha-Mannosidosis

Interventions

Type	Name	Description
DRUG	Lamazym	ERT, i.v. infusions weekly

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-08-01
• Completion: 2013-09-01
• First posted: 2012-09-10
• Last updated: 2017-03-29

Locations

4 sites across 4 countries: Belgium, Denmark, Spain, United Kingdom